北京大学医学部机构知识库
Advanced  
 E 
IR@PKUHSC  > 北京大学临床肿瘤学院  > 乳腺癌预防治疗中心  > 期刊论文
学科主题: 临床医学
题名:
Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer
作者: Yuan, Hua1; Chen, Jiuan1; Liu, Yiqiang1; Ouyang, Tao1; Li, Jinfeng1; Wang, Tianfeng1; Fan, Zhaoqing1; Fan, Tie1; Lin, Benyao1; Xie, Yuntao1
刊名: CLINICAL CANCER RESEARCH
发表日期: 2015-10-01
DOI: 10.1158/1078-0432.CCR-14-3354
卷: 21, 期:19, 页:4365-4372
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: FACTOR RECEPTOR 2 ; PHOSPHATIDYLINOSITOL 3-KINASE ; TENSIN HOMOLOG ; PTEN LOSS ; TRASTUZUMAB ; ACTIVATION ; PATHWAY ; GENE ; RESISTANCE ; PHOSPHATASE
英文摘要:

Purpose: The association between PIK3CA mutations and response to neoadjuvant chemotherapy in women with primary breast cancer is not fully elucidated.

Experimental Design: PIK3CA mutations in breast cancer tissues that were taken prior to the initiation of neoadjuvant chemotherapy were identified in 729 operable primary breast cancer patients who received neoadjuvant chemotherapy. Among these, the PIK3CA mutations were also reassessed in tumor tissues procured following operation in 102 patients after completion of neoadjuvant chemotherapy.

Results: A total of 206 out of 729 (28.3%) patients had PIK3CA mutations, and 19.5% of patients (142/729) in this cohort achieved a pathologic complete response (pCR) after neoadjuvant chemotherapy. Patients with PIK3CA mutations exhibited a lower pCR rate than did those with wild-type (14.6% vs. 21.4%, P = 0.035). No significant differences in disease-free survival (DFS) or distant disease-free survival (DDFS) were observed between PIK3CA mutant and wild-type in the entire study population. Among the 102 patients with PIK3CA mutation statuses available before and after neoadjuvant chemotherapy, 24 patients (23.5%) had PIK3CA mutations before neoadjuvant chemotherapy. Of these 24 patients, 15 patients retained their initial PIK3CA mutations and 9 patients lost their initial mutations after neoadjuvant chemotherapy. Patients who retained the initial mutations after neoadjuvant chemotherapy (n = 15) had a worse DDFS than the remaining patients (n = 87) in this subgroup [unadjusted HR, 2.34; 95% confidence interval (CI), 0.98-5.62; P = 0.050].

Conclusions: Patients with PIK3CA mutations are less likely to respond to neoadjuvant chemotherapy. Patients who retain their initial PIK3CA mutations after neoadjuvant chemotherapy have an unfavorable survival. (C) 2015 AACR.

语种: 英语
所属项目编号: 2014BAI09B08 ; 2013CB911004 ; 30973436 ; 81071629
项目资助者: National Key Technology Research and Development Program of the Ministry of Science and Technology of China ; 973 project ; 985-III project ; National Natural Science Foundation of China
WOS记录号: WOS:000363330500018
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/51281
Appears in Collections:北京大学临床肿瘤学院_乳腺癌预防治疗中心_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ Canc Hosp & Inst, Breast Ctr, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
2.Peking Univ Canc Hosp & Inst, Dept Pathol, Beijing, Peoples R China

Recommended Citation:
Yuan, Hua,Chen, Jiuan,Liu, Yiqiang,et al. Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer[J]. CLINICAL CANCER RESEARCH,2015,21(19):4365-4372.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Yuan, Hua]'s Articles
[Chen, Jiuan]'s Articles
[Liu, Yiqiang]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Yuan, Hua]‘s Articles
[Chen, Jiuan]‘s Articles
[Liu, Yiqiang]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace